<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04615312</url>
  </required_header>
  <id_info>
    <org_study_id>CRC-PANC-IIT-SHR6390-SHR7390</org_study_id>
    <nct_id>NCT04615312</nct_id>
  </id_info>
  <brief_title>A Trail of CDK4 / 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors</brief_title>
  <official_title>Phase I Clinical Study on the Safety and Tolerability of a CDK4 / 6 Inhibitor and a MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open, phase I clinical study to evaluate the safety and tolerability&#xD;
      of a CDK4 / 6 inhibitor and a MEK inhibitor in the treatment of metastatic digestive system&#xD;
      tumors&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 14, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose of a CDK4 / 6 inhibitor and a MEK inhibitor therapy</measure>
    <time_frame>Up to approximately 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>the Objective Remission Rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Digestive System Tumors</condition>
  <arm_group>
    <arm_group_label>a CDK4 / 6 inhibitor and a MEK inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a CDK4 / 6 inhibitor and a MEK inhibitor treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>a CDK4 / 6 inhibitor and a MEK inhibitor</intervention_name>
    <description>Participant will receive a CDK4 / 6 inhibitor and a MEK inhibitor treatment to determine the maximum tolerated dose</description>
    <arm_group_label>a CDK4 / 6 inhibitor and a MEK inhibitor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18-75 years;&#xD;
&#xD;
          2. ECOG score â‰¤ 1;&#xD;
&#xD;
          3. Patients with advanced KRAS mutation or metastatic digestive system tumor confirmed by&#xD;
             histology or cytology and imaging diagnosis;&#xD;
&#xD;
          4. According to Recist1.1, there was at least one measurable lesion;&#xD;
&#xD;
          5. The expected survival time was more than 12 weeks;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who received any anti-tumor treatment within 4 weeks before enrollment,&#xD;
             including radiotherapy, chemotherapy, molecular targeted therapy and immunotherapy, or&#xD;
             participated in another intervention clinical trial;&#xD;
&#xD;
          2. Previous treatment with targeted BRAF, MEK, ERK or CDK family related inhibitors;&#xD;
&#xD;
          3. The third space effusion (such as massive pleural effusion or ascites) with clinical&#xD;
             symptoms that cannot be controlled by drainage or other methods;&#xD;
&#xD;
          4. Allergy to any test drug and its excipients, or serious allergic history, or&#xD;
             contraindication of the test drug;&#xD;
&#xD;
          5. Have a history of immunodeficiency, including HIV positive, or other acquired,&#xD;
             congenital immunodeficiency diseases, or a history of organ transplantation;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ning Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Suxia Luo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ning Li, PhD</last_name>
    <phone>13526501903</phone>
    <email>lining97@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ning Li, PhD</last_name>
      <phone>0086-13526501903</phone>
      <email>lining97@126.com</email>
    </contact>
    <investigator>
      <last_name>Ning Li, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suxia Luo, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henan Cancer Hospital</investigator_affiliation>
    <investigator_full_name>LiNing</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

